CD4 Mimetic Compounds for HIV Env Epitope Unmasking

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

HIV-1 has evolved mechanisms to conceal epitopes in its envelope glycoprotein (Env) that are recognized by ADCC-mediating antibodies, making it difficult to eliminate infected cells effectively.

Innovation Solution

Development of small molecule CD4 mimetic compounds (CD4mc) that modulate Env conformation to unmask CD4i epitopes, sensitizing HIV-1 infected cells to antibody-dependent cellular cytotoxicity (ADCC) by enhancing the recognition and binding of the core field of the technical solution, thus allowing enhanced recognition and binding by antibodies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If HIV-1 envelope glycoprotein (Env) conceals epitopes to avoid immune detection, then viral immune evasion is improved, but antibody recognition and ADCC effectiveness deteriorate

Engineering Contradiction:

Improveviral immune evasionVSAvoidantibody recognition effectiveness

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent applies parameter changes by modifying the conformational state of the HIV-1 envelope glycoprotein through small molecule CD4 mimetic compounds. These compounds induce structural transitions in Env that expose previously concealed CD4i epitopes, thereby changing the physical-chemical parameters of the viral surface and making it recognizable by ADCC-mediating antibodies while maintaining immune evasion characteristics

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention employs preliminary action by using small molecule CD4 mimetics to pre-modulate the Env conformation before antibody binding occurs. The compounds bind to Env and induce an open conformation that exposes epitopes in advance, preparing the viral surface for subsequent antibody recognition and ADCC-mediated cell killing

Inventive Principle:

Principle #10Preliminary action

2Manufacturing precision

If soluble CD4 (sCD4) is used to modulate Env conformation, then epitope unmasking is improved, but molecular size and complexity increase

Engineering Contradiction:

Improveepitope unmasking precisionVSAvoidmolecule size

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent extracts the essential functional moiety from the large soluble CD4 protein to create small molecule CD4 mimetics. By taking out only the critical binding and conformational-modulating elements of sCD4, the invention achieves epitope unmasking functionality while dramatically reducing molecular size and complexity, making the compounds more suitable for drug development

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention creates simplified copies of the CD4 molecule that replicate its key functions. The small molecule CD4 mimetics are designed to copy the essential interaction patterns of full-length CD4 with Env, inducing the same conformational changes and exposing the same epitopes, but with much smaller molecular structures that are easier to produce and administer

Inventive Principle:

Principle #26Copying

Data Source

PatentUS20260001844A1Compounds and methods for the treatment and prevention of HIV

Publication Date: 2026.01.01 THE HENRY M JACKSON FOUND FOR THE ADVANCEMENT OF MILITARY MEDICINE INC

AI summary

Compositions and methods for treating HIV using compounds that sensitize HIV-1 infected cells to antibody-dependent cellular cytotoxicity.